LNAI

Lunai Bioworks Inc.

LNAI.US lunaibioworks.com
2.44
-0.18 (-6.71%)
USD · NASDAQ
52-week range
1.21
17.52
Trading at 8% of the 52-week range
Market Cap
11.83M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
-2.14
Div. Yield
N/A
% Institutions
3.53%
% Insiders
40.72%

1 Year

-85.3%

3 Year

-99.2%

10 Year

-69.6%
Description

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.

Company Information

Company Name
Lunai Bioworks Inc.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US29350E3027
Currency: USD
Full Time Employees: 29
Phone: 305 918 1980
Fiscal Year End: June
IPO Date: Feb 02, 2015
Description:

Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States and the Netherlands. It operates through three segments, RENB, BioSymetrics, and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is headquartered in Los Angeles, California.

Address:

2080 Century Park East, Los Angeles, CA, United States, 90067

People

Directors & Officers

Name Title Year Born
Mr. David H. Weinstein CEO & Director 1961
Mr. Nathen Fuentes CPA Chief Financial Officer 1983

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Geode Capital Management, LLC 182.24K Mar 31, 2026 0.50% $0.00 39.10%
BlackRock Inc 127.31K Mar 31, 2026 0.35% $0.00 0.00%
Nine Masts Capital Limited 102.43K Mar 31, 2026 0.28% $0.01 322.90%
Citigroup Inc 100.10K Mar 31, 2026 0.28% $0.00 0.00%
Vanguard Capital Management, LLC 96.50K Mar 31, 2026 0.27% $0.00 0.00%
Virtu Financial LLC 75.18K Mar 31, 2026 0.21% $0.00 0.00%
Vanguard Fiduciary Trust Co 69.14K Mar 31, 2026 0.19% $0.00 0.00%
Ground Swell Capital, LLC 53.21K Jun 30, 2026 1.17% $0.19 0.00%
XTX Topco Ltd 52.48K Mar 31, 2026 0.14% $0.00 0.00%
Northern Trust Corp 37.40K Mar 31, 2026 0.10% $0.00 0.00%
State Street Corp 35.73K Mar 31, 2026 0.10% $0.00 0.00%
TWO SIGMA SECURITIES, LLC 25.10K Mar 31, 2026 0.07% $0.00 0.00%
Jump Financial LLC 19.46K Mar 31, 2026 0.05% $0.00 0.00%
Scientech Research LLC 13.67K Mar 31, 2026 0.04% $0.00 0.00%
The Goldman Sachs Group Inc 12.08K Mar 31, 2026 0.03% $0.00 11.16%
UBS Group AG 11.44K Mar 31, 2026 0.03% $0.00 -36.24%
Tower Research Capital LLC 4.70K Mar 31, 2026 0.01% $0.00 -19.87%
Group One Trading, LLC 4.36K Mar 31, 2026 0.01% $0.00 134.41%
Vanguard Global Advisers, LLC 4.33K Mar 31, 2026 0.01% $0.00 0.00%
Morgan Stanley - Brokerage Accounts 2.61K Mar 31, 2026 0.01% $0.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard Institutional Extnd Mkt Idx Tr 49.98K 1.10% ▲ 210.78% Jul 31, 2026
2 Extended Equity Market Fund E 20.84K 0.06% ▲ 0.00% Dec 31, 2025
3 Extended Equity Market Fund B 20.84K 0.06% ▲ 0.00% Dec 31, 2025
4 Fidelity Extended Market Index 17.83K 0.39% ▲ 0.00% Jul 31, 2026
5 NT Ext Eq Mkt Idx Fd DC Lending Tier 5 10.10K 0.03% ▲ 0.70% Mar 31, 2026
6 Northern Trust Extended Eq Market Idx 3.20K 0.07% ▼ 0.03% Jun 30, 2026
7 NT Ext Equity Mkt Index Fund - Lending 3.20K 0.07% ▼ 0.03% Jun 30, 2026
8 NT Ext Equity Mkt Index Fund - NL 3.10K 0.07% ▲ 118.09% Jun 30, 2026
9 Blackrock Extended Mkt Fund CF 2.61K 0.06% ▲ 0.00% May 31, 2026
10 NT Ext Equity Mkt Idx Fd - DC - NL - T2 2.25K 0.05% ▲ 101.98% Jun 30, 2026

Financial Highlights

Market Cap: $11.83M
EBITDA: $-9.77M
Book Value: $-2.14
Earnings/Share: $-62.72
Profit Margin: 0.00%
Operating Margin: -6,815.30%
ROA (TTM): -9.65%
ROE (TTM): -325.46%
Revenue (TTM): $20.94K
Revenue/Share (TTM): $0.01
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $9.86M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 4.53M
Shares Float: 2.92M
% Insiders: 40.72%
% Institutions: 3.53%
Short % Float: 3.94%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-129.09K
Gross Profit
subtotal
$-129.09K
SG&A
adjust
$-17.88M
R&D
adjust
$-537.43K
Operating Income
subtotal
$-18.55M
Other / Non-Operating Items
adjust
$-159.46M
Net Income
subtotal
$-178.01M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about LNAI.US!